<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">World J Surg Oncol</journal-id>
      <journal-title>World Journal of Surgical Oncology</journal-title>
      <issn pub-type="epub">1477-7819</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">18318916</article-id>
      <article-id pub-id-type="pmc">2292185</article-id>
      <article-id pub-id-type="publisher-id">1477-7819-6-30</article-id>
      <article-id pub-id-type="doi">10.1186/1477-7819-6-30</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Extensive necrosis of visceral melanoma metastases after immunotherapy</article-title>
      </title-group>
      <contrib-group>
        <contrib id="A1" corresp="yes" contrib-type="author">
          <name>
            <surname>Stoeter</surname>
            <given-names>David</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>joelstoeter@doctors.org.uk</email>
        </contrib>
        <contrib id="A2" contrib-type="author">
          <name>
            <surname>de Liguori Carino</surname>
            <given-names>Nicola</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>nicola.dlc@gmail.com</email>
        </contrib>
        <contrib id="A3" contrib-type="author">
          <name>
            <surname>Marshall</surname>
            <given-names>Ernest</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>emarshall@nhs.net</email>
        </contrib>
        <contrib id="A4" contrib-type="author">
          <name>
            <surname>Poston</surname>
            <given-names>Graeme J</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>graemeposton@blueyonder.co.uk</email>
        </contrib>
        <contrib id="A5" contrib-type="author">
          <name>
            <surname>Wu</surname>
            <given-names>Andrew</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>wuvoonon@mac.com</email>
        </contrib>
      </contrib-group>
      <aff id="I1"><label>1</label>The Department of Hepatobiliary Surgery, Aintree University Hospital NHS Foundation Trust, Lower Lane, Fazakerley, Liverpool, L9 7AL, UK</aff>
      <aff id="I2"><label>2</label>The Clatterbridge Centre for Oncology NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY, UK</aff>
      <pub-date pub-type="collection">
        <year>2008</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>4</day>
        <month>3</month>
        <year>2008</year>
      </pub-date>
      <volume>6</volume>
      <fpage>30</fpage>
      <lpage>30</lpage>
      <ext-link ext-link-type="uri" xlink:href="http://www.wjso.com/content/6/1/30"/>
      <history>
        <date date-type="received">
          <day>19</day>
          <month>6</month>
          <year>2007</year>
        </date>
        <date date-type="accepted">
          <day>4</day>
          <month>3</month>
          <year>2008</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2008 Stoeter et al; licensee BioMed Central Ltd.</copyright-statement>
        <copyright-year>2008</copyright-year>
        <copyright-holder>Stoeter et al; licensee BioMed Central Ltd.</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0">
          <p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p>
          <!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author>
               Stoeter
               David
               
               joelstoeter@doctors.org.uk
            </dc:author><dc:title>
            Extensive necrosis of visceral melanoma metastases after immunotherapy
         </dc:title><dc:date>2008</dc:date><dcterms:bibliographicCitation>World Journal of Surgical Oncology 6(1): 30-. (2008)</dcterms:bibliographicCitation><dc:identifier type="sici">1477-7819(2008)6:1&#x0003c;30&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1477-7819</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>-->
        </license>
      </permissions>
      <abstract>
        <sec>
          <title>Background</title>
          <p>The prognosis for metastatic melanoma remains poor even with traditional decarbazine or interferon therapy. 5-year survival is markedly higher amongst patients undergoing metastatectomy. Unfortunately not all are suitable for metastatectomy. Alternative agents for systemic therapy have, to date, offered no greater rates of survival beyond traditional therapy. A toll-like receptor 9 agonist, PF-3512676 (formerly known as CPG 7909) is currently being evaluated for its potential.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>We present the case of a 54-year-old Caucasian male with completely resected metastatic cutaneous melanoma after immunotherapy. The patient initially progressed during adjuvant high-dose interferon, with metastases to the liver, spleen, and pelvic lymph nodes. During an 18-month treatment period with PF-3512676 (formerly known as CPG 7909), a synthetic cytosine-phosphorothioate-guanine rich oligodeoxynucleotide, slow radiologic disease progression was demonstrated at the original disease sites. Subsequent excision of splenic and pelvic nodal metastases was performed, followed by resection of the liver metastases. Histologic examination of both hepatic and splenic melanoma metastases showed extensive necrosis. Subsequent disease-free status was demonstrated by serial positron emission tomography (PET).</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>Existing evidence from phase I/II trials suggests systemic treatment with PF-3512676 is capable of provoking a strong tumor-specific immune response and may account for the prolonged tumor control in this instance.</p>
        </sec>
      </abstract>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Background</title>
      <p>Metastasis is by far the most common cause of death in patients with malignant melanoma, with estimated rates of cutaneous malignant melanoma metastasis of approximately 14% [<xref ref-type="bibr" rid="B1">1</xref>]. Furthermore, only about 7% of metastatic melanoma cases are suitable for metastasectomy. In general, less than 6% of patients with metastatic disease survive up to 5 years, but in those undergoing complete resection, survival approaches 25% at 5 years [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>]. In patients unsuitable for surgical intervention, systemic therapy with dacarbazine remains the standard of care with few long-term survivors and a median survival of only 6 months [<xref ref-type="bibr" rid="B4">4</xref>]. A number of novel agents are currently undergoing evaluation with the hope of improving outcomes beyond traditional therapy [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>]. The case report we present describes unique radiological and histopathological responses to one particular new agent: PF-3512676.</p>
    </sec>
    <sec>
      <title>Case presentation</title>
      <p>A 54-year-old Caucasian male presented with a 1.5 mm Breslow malignant melanoma on his left shin in February 2002 and was managed with wide local excision. At 16 months follow-up, recurrence in the left inguinal lymph nodes was detected. The patient underwent groin dissection, and all 8 lymph nodes showed either partial or complete replacement by metastatic melanoma on histology with extracapsular extension. No necrosis was seen in either the skin or the lymph node specimens at this stage. Surgery was followed by adjuvant high-dose interferon-&#x3B1;2a therapy, consisting of 1 month of intravenous interferon 5 days a week followed by 11 months of subcutaneous lower-dose interferon 3 days a week. Progression was documented at 6 months by computed tomography (CT), which confirmed a large metastasis in the spleen, left iliac lymphadenopathy, and 2metastases in the liver (Figure <xref ref-type="fig" rid="F1">1</xref>).</p>
      <fig position="float" id="F1">
        <label>Figure 1</label>
        <caption>
          <p><bold>Computed tomography (CT) of the abdomen and pelvis</bold>. CT scanning immediately before initial pelvic tumor debulking at 46 months after presentation shows A). Large splenic metastasis (100.3 mm), B). Metastasis to the left iliac vein lymph nodes (41.3 mm), and C). A slightly lower view of the splenic metastasis showing the 2 liver lesions. D). CT of the abdomen, post-splenectomy and pelvic tumor debulking, and pre-liver resection (2 liver metastases 20 mm and 15 mm in segments V and VI) at 51 months.</p>
        </caption>
        <graphic xlink:href="1477-7819-6-30-1"/>
      </fig>
      <p>The patient enrolled into a randomized phase II clinical trial in which he was treated with the toll-like receptor 9 agonist PF-3512676 (formerly known as CPG 7909), a synthetic cytosine-phosphorothioate-guanine rich oligodeoxynucleotide. PF-3512676 induces activation of plasmacytoid dendritic cells and enhances cell surface expression of costimulatory molecules (eg, B7) and is hypothesized to promote an antitumor immune response by enhancing antigen presentation to T cells and promoting proliferation of antigen-specific cytotoxic T lymphocytes. CT scanning was performed during the study initially 6 weekly for 6 months, then at 8 weekly intervals. The patient achieved stable disease over a 20-month period. Thereafter, disease progression, according to RECIST radiological parameters [<xref ref-type="bibr" rid="B7">7</xref>], was documented at all disease sites. It is worth noting that during the therapy period, the patient experienced grade 1cutaneous reaction (minor erythema) at the site of the excised primary lesion, the left shin. Figure <xref ref-type="fig" rid="F1">1A&#x2013;C</xref> shows the 100.3 mm splenic metastasis (Figure <xref ref-type="fig" rid="F1">1A</xref>), the 41.3 mm pelvic metastases along the left iliac vein lymph node chain (Figure <xref ref-type="fig" rid="F1">1B</xref>), and the 2 metastatic liver lesions (Figure <xref ref-type="fig" rid="F1">1C</xref> and <xref ref-type="fig" rid="F1">1D</xref>) shortly after completion of the PF-3512676 treatment period. In view of the indolent disease biology and the absence of new metastatic lesions during treatment, tumor metastasectomy was undertaken. Initial left iliac lymphadenectomy and splenectomy was followed by adjuvant pelvic radiotherapy. During a second procedure, the patient underwent staging laparoscopy followed by liver resection of segments V and VI with cholecystectomy. Surgical clearance was confirmed by whole body PET scanning at 1 month and 6 months after liver resection, indicating no disease activity. Following up imaging is currently being performed with 3 monthly alternating CT and PET scanning.</p>
      <sec>
        <title>Histology findings</title>
        <p>Macroscopic examination of the liver lesions revealed a dark brown nodule (25 &#xD7; 20 &#xD7; 15 mm) comprised of 2 adjoining lesions reaching the liver capsule but remaining clear of the resection margin. Sections throughout the specimen revealed an almost entirely necrotic nodule with a well-demarcated fibrous capsule (Figure <xref ref-type="fig" rid="F2">2</xref>). Many of the cells within the inner margin of the capsule contained a granular brown pigment showing no reaction in Perl's preparation. However, because of loss of color when placed in a melanin bleach preparation, the pigment was identified as melanin. The majority of these pigmented cells tested positive for CD68, indicating that they were macrophages. In contrast, a very few number of cells tested positive for S100, indicating that these cells were melanoma. Hence, the vast majority of these pigmented cells were macrophages, with only a small number identified as melanoma cells.</p>
        <fig position="float" id="F2">
          <label>Figure 2</label>
          <caption>
            <p><bold>Photomicrograph of liver metastases</bold>. A). Liver metastasis showing almost complete necrosis within a fibrous capsule. Cells adjacent to the capsule contain a brown pigment. B). The pigment disappears in melanin bleach preparation. C). Very few cells stained positive for S100. In this section, only 1 positive cell was observed, staining a homogeneous dark brown color compared with the dotted granular brown appearance of neighboring cells. D). The majority of the pericapsular cells containing melanin stained positive for CD68, indicating that they are macrophages.</p>
          </caption>
          <graphic xlink:href="1477-7819-6-30-2"/>
        </fig>
        <p>The spleen specimen also showed a similar histologic pattern, with almost the entire parenchyma replaced by friable necrotic tissue. Moreover, sections contained large areas of necrosis with admixed melanoma cells. In addition, the left iliac specimen was largely hemorrhagic with blood clots, fibroadipose tissue, and deposits of viable malignant melanoma.</p>
      </sec>
    </sec>
    <sec>
      <title>Discussion</title>
      <p>This case report illustrates the potential role for metastasectomy in selected cases of metastatic melanoma, despite multiple disease sites. The history of this patient followed a remarkably indolent course on PF-3512676 therapy, even with early recurrence on high-dose interferon. Although progressive disease was documented according to RECIST criteria, there was in fact minor enlargement of the known disease over a number of months. The pathology suggests an inflammatory response to account for the latter, but it remains unclear whether the history was a consequence of indolent biology or therapy.</p>
      <p>Malignant melanoma is known to be 1 of 3 types of malignancies with a particular tendency to spontaneously regress. The other 2 types of malignancies are neuroblastoma and renal cell carcinoma [<xref ref-type="bibr" rid="B8">8</xref>]. Malignant melanoma accounts for 11% of all reported cases of spontaneous cancer regression but only contributes 1.8% of the total incidence of all types of cancer. However, most of these regressions are partial and rarely occur in metastatic cases (0.22% to 0.27% of all malignant melanoma cases) [<xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B13">13</xref>]. Regression of visceral metastatic melanoma compared with local cutaneous, subcutaneous, and lymph node spread is exceptionally rare [<xref ref-type="bibr" rid="B11">11</xref>-<xref ref-type="bibr" rid="B13">13</xref>]. In addition, spontaneous regression of visceral melanoma metastases appears to be short-lived, with only 1 case in the literature demonstrating long-term regression [<xref ref-type="bibr" rid="B14">14</xref>]. The observations in this patient suggest that immunotherapy with PF-3512676 may have contributed to the necrosis of metastatic lesions.</p>
      <p>The traditional approach to metastatic melanoma remains systemic therapy, with no consistent survival advantage reported with multiagent therapy. Immune therapy-based treatment may induce more durable remissions than standard chemotherapy in highly selected patients; however, a survival advantage has not been confirmed from randomized clinical trials [<xref ref-type="bibr" rid="B15">15</xref>]. Even the more recent, experimental agents (IL-2, IL-12, Granulocyte Macrophage-Colony Stimulating Factor and antigen vaccines as well as agents aimed at inhibiting oncogene activity) have showed no clinical benefit over decarbazine in Phase III trials in terms of progression-free survival [<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B17">17</xref>]. Success of immunotherapy has been limited by the difficult challenge of provoking an adequate immune response while limiting toxicity. The more recent approaches, aimed at directing the immune response to the tumor cells alone, involve using tumor antigens to produce vaccines. This approach has been applied to Bcell lymphomas and melanomas. However, many vaccines have been proven to be poorly immunogenic and this appears to be due, in part at least, to the immune-dampening effect of the tumor environment. Certain factors have been found to inhibit (e.g. Tregs) or prevent the maturation of an adequate anti-tumor immune response [<xref ref-type="bibr" rid="B17">17</xref>]. As such, the search for suitable vaccine adjuvants has been ongoing.</p>
      <p>In this case study, a toll-like receptor 9 agonist (PF-3512676) composed of cytosine-phosphorothioate-guanine (CpG)-rich oligodeoxynucleotides was the treatment used. These nucleotides act analogously to bacterial DNA by directly activating plasmacytoid dendritic cells and plasma cells and inducing both T- and B-cell responses as well as cytokine (e.g. interferon-&#x3B1;) production [<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B19">19</xref>]. These CpG-rich oligodeoxynucleotides have exhibited evidence of augmenting immune responses to both tumor vaccines and interferon [<xref ref-type="bibr" rid="B15">15</xref>] and are currently being evaluated in clinical trials in refractory/relapsing breast cancer, advanced small cell lung cancer, and melanoma [<xref ref-type="bibr" rid="B19">19</xref>].</p>
      <p>A recent phase I trial, in 8 patients with advanced melanoma, of PF-3512676 with melanoma antigen (Melan A26) compared levels of melanoma-specific cytotoxic T-cells generated by the PF-3512676 vaccine with another vaccine that had demonstrated some success in mice but minimal effect in humans [<xref ref-type="bibr" rid="B18">18</xref>]. The PF-3512676 vaccine generated a 43-fold increase in melanoma-specific T-cells compared with prevaccination. This increase was 23 times the level observed with the other vaccine. Reported side effects experienced by the majority of patients included transient malaise, nausea, myalgia, arthralgia, headaches, and fatigue. All patients also experienced inflammation at the injection site on each vaccination. In another study, the combination of interferon &#x3B1; and CpG oligodeoxynucleotides was shown to have additive antitumor activity in murine models of melanoma [<xref ref-type="bibr" rid="B20">20</xref>]. Results indicated that CpG oligodeoxynucleotides appeared to greatly enhance tumor infiltration compared with interferon.</p>
      <p>Another placebo-controlled Phase II trial looked at the effect of PF3512676 on the immunological response at the sentinel lymph node in patients with early stage melanoma. Results showed a significant increase in the number of mature dendritic cells capable of stimulating T-cells and a reduction in Treg immunosuppression [<xref ref-type="bibr" rid="B21">21</xref>].</p>
      <p>Most of the phase II trials to date have been directed more at investigating the effects of PF-3512676 on the host immune system and less on actual clinical outcomes of patients, in a bid to first elicit the molecular and cellular mechanisms of action to provide a biological basis for its use in humans. However one recent phase II trial of single-agent PF-3512676 for 24 weeks in patients (N = 20) with metastatic melanoma was performed with an analysis of clinical response as measured by the RECIST parameters [<xref ref-type="bibr" rid="B22">22</xref>]. Two patients experienced a partial response, and three patients had stable disease for 8 weeks, and then progressed. The remainder progressed throughout the trial. Responses were observed in lung, skin, and soft tissue. Treatment duration and follow up was much shorter than that performed in our patient. Patient numbers were also small.</p>
    </sec>
    <sec>
      <title>Conclusion</title>
      <p>The case we present here appears to be the only such case in the literature reporting evidence of necrosis of extensive visceral metastases in response to this new form of immunotherapy. The data above suggest that PF-3512676 is capable of inducing a strong tumor antigen-specific T-cell response when used with tumor vaccines and can induce marked necrosis in melanoma metastases when used as a single agent. An ongoing phaseI/II clinical trial using 2 different doses of PF-3512676 has indicated no dose-related differences in side effect profiles to date. However, the balance between tumor response and toxicity requires further attention [<xref ref-type="bibr" rid="B23">23</xref>]. The majority of research on CpG oligodeoxynucleotides to date has focused on eliciting cellular mechanisms in animal models. Results from current and new clinical trials in humans are awaited to evaluate clinical responses.</p>
    </sec>
    <sec>
      <title>Competing interests</title>
      <p>The author(s) declare that they have no competing interests.</p>
    </sec>
    <sec>
      <title>Authors' contributions</title>
      <p>DS the compilation and writing of the article, NDLC concept and supervision of the writing of the article, EM contributions to the content of the article and revisions of the final manuscript, AW the operating Surgeon and overseer of the writing of the article.</p>
      <p>All authors read and approved the manuscript.</p>
    </sec>
  </body>
  <back>
    <ack>
      <sec>
        <title>Acknowledgements</title>
        <p>C. T. Burrow (Consultant Pathologist providing the histology slides for the article), D White (Consultant Radiologist providing the CT slides for the article)</p>
        <p>Written consent was obtained from the patient for publication of this case report.</p>
      </sec>
    </ack>
    <ref-list>
      <ref id="B1">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hmad</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Arhini</surname>
              <given-names>AT</given-names>
            </name>
            <name>
              <surname>Anjiv</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Garwala</surname>
              <given-names>SA</given-names>
            </name>
          </person-group>
          <article-title>Cutaneous melanoma: available therapy for metastatic disease</article-title>
          <source>Dermatol Ther</source>
          <year>2006</year>
          <volume>19</volume>
          <fpage>19</fpage>
          <lpage>25</lpage>
          <pub-id pub-id-type="pmid">16405566</pub-id>
          <pub-id pub-id-type="doi">10.1111/j.1529-8019.2005.00052.x</pub-id>
        </citation>
      </ref>
      <ref id="B2">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wood</surname>
              <given-names>TF</given-names>
            </name>
            <name>
              <surname>DiFronzo</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Rose</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Haigh</surname>
              <given-names>PI</given-names>
            </name>
            <name>
              <surname>Stern</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Wanek</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Essner</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Morton</surname>
              <given-names>DL</given-names>
            </name>
          </person-group>
          <article-title>Does Complete Resection of Melanoma Metastatic to Solid Intra-Abdominal Organs Improve Survival?</article-title>
          <source>Ann Surg Oncol</source>
          <year>2001</year>
          <volume>8</volume>
          <fpage>658</fpage>
          <lpage>662</lpage>
          <pub-id pub-id-type="pmid">11569781</pub-id>
          <pub-id pub-id-type="doi">10.1007/s10434-001-0658-4</pub-id>
        </citation>
      </ref>
      <ref id="B3">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sharpless</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Gupta</surname>
              <given-names>TKD</given-names>
            </name>
          </person-group>
          <article-title>Surgery for Metastatic Melanoma</article-title>
          <source>Semin Surg Oncol</source>
          <year>1998</year>
          <volume>14</volume>
          <fpage>311</fpage>
          <lpage>318</lpage>
          <pub-id pub-id-type="pmid">9588724</pub-id>
          <pub-id pub-id-type="doi">10.1002/(SICI)1098-2388(199806)14:4&lt;311::AID-SSU7&gt;3.0.CO;2-5</pub-id>
        </citation>
      </ref>
      <ref id="B4">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Khan</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Andrews</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ismail-Khan</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Munster</surname>
              <given-names>PN</given-names>
            </name>
            <name>
              <surname>Brem</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>King</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Reintgen</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Sondak</surname>
              <given-names>VK</given-names>
            </name>
            <name>
              <surname>Daud</surname>
              <given-names>AI</given-names>
            </name>
          </person-group>
          <article-title>Overall and progression-free survival in metastatic melanoma: analysis of a single-institution database</article-title>
          <source>Cancer Control</source>
          <year>2006</year>
          <volume>13</volume>
          <fpage>211</fpage>
          <lpage>217</lpage>
          <pub-id pub-id-type="pmid">16885917</pub-id>
        </citation>
      </ref>
      <ref id="B5">
        <citation citation-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Lorigan</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Corrie</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Chao</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Nathan</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ahmad</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Marais</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Burk</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Erlandsson</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Gore</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Eisen</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Phase II trial of sorafenib combined with dacarbazine in metastatic melanoma patients</article-title>
          <source>J Clin Oncol</source>
          <year>2006</year>
          <volume>24</volume>
          <publisher-name>ASCO Annual Meeting Proceedings</publisher-name>
          <fpage>8012</fpage>
        </citation>
      </ref>
      <ref id="B6">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bedikian</surname>
              <given-names>AY</given-names>
            </name>
            <name>
              <surname>Millward</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Pehamberger</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Conry</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Gore</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Trefzer</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Pavlick</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>DeConti</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Hersh</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Hersey</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Kirkwood</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Haluska</surname>
              <given-names>FG</given-names>
            </name>
          </person-group>
          <article-title>Bcl-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen. Melanoma Study Group</article-title>
          <source>J Clin Oncol</source>
          <year>2006</year>
          <volume>24</volume>
          <fpage>4738</fpage>
          <lpage>4745</lpage>
          <pub-id pub-id-type="pmid">16966688</pub-id>
          <pub-id pub-id-type="doi">10.1200/JCO.2006.06.0483</pub-id>
        </citation>
      </ref>
      <ref id="B7">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Padhani</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Ollivier</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>The RECIST criteria: implications for diagnostic radiologists</article-title>
          <source>Br J Radiol</source>
          <year>2001</year>
          <volume>74</volume>
          <fpage>983</fpage>
          <lpage>986</lpage>
          <pub-id pub-id-type="pmid">11709461</pub-id>
        </citation>
      </ref>
      <ref id="B8">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>King</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Spooner</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Rowlands</surname>
              <given-names>DC</given-names>
            </name>
          </person-group>
          <article-title>Spontaneous regression of metastatic malignant melanoma of the Parotid Gland and Neck Lymph Nodes: a Case Report and a Review of the Literature</article-title>
          <source>Clin Oncol</source>
          <year>2001</year>
          <volume>13</volume>
          <fpage>466</fpage>
          <lpage>469</lpage>
        </citation>
      </ref>
      <ref id="B9">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>TS</given-names>
            </name>
            <name>
              <surname>Lowe</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>JW</given-names>
              <suffix>2nd</suffix>
            </name>
            <name>
              <surname>Francis</surname>
              <given-names>IR</given-names>
            </name>
            <name>
              <surname>Sondak</surname>
              <given-names>VK</given-names>
            </name>
            <name>
              <surname>Dworzanian</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Finkelstein</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Slingluff</surname>
              <given-names>CL</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>TM</given-names>
            </name>
          </person-group>
          <article-title>Complete spontaneous regression of pulmonary metastatic melanoma</article-title>
          <source>Dermatol Surg</source>
          <year>1998</year>
          <volume>24</volume>
          <fpage>915</fpage>
          <lpage>919</lpage>
          <pub-id pub-id-type="pmid">9723062</pub-id>
          <pub-id pub-id-type="doi">10.1016/S1076-0512(98)00093-4</pub-id>
        </citation>
      </ref>
      <ref id="B10">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shai</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Avinoach</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Sagi</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Metastatic malignant melanoma with spontaneous and complete regression of the primary lesion. Case report and review of the literature</article-title>
          <source>J Dermatol Surg Oncol</source>
          <year>1994</year>
          <volume>20</volume>
          <fpage>342</fpage>
          <lpage>345</lpage>
          <pub-id pub-id-type="pmid">8176047</pub-id>
        </citation>
      </ref>
      <ref id="B11">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hurwitz</surname>
              <given-names>PJ</given-names>
            </name>
          </person-group>
          <article-title>Spontaneous regression of metastatic melanoma</article-title>
          <source>Ann Plast Surg</source>
          <year>1991</year>
          <volume>26</volume>
          <fpage>403</fpage>
          <lpage>406</lpage>
          <pub-id pub-id-type="pmid">1872546</pub-id>
          <pub-id pub-id-type="doi">10.1097/00000637-199104000-00016</pub-id>
        </citation>
      </ref>
      <ref id="B12">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mikhail</surname>
              <given-names>GR</given-names>
            </name>
            <name>
              <surname>Gorsulowsky</surname>
              <given-names>DC</given-names>
            </name>
          </person-group>
          <article-title>Spontaneous regression of metastatic malignant melanoma</article-title>
          <source>J Dermatol Surg Oncol</source>
          <year>1986</year>
          <volume>12</volume>
          <fpage>497</fpage>
          <lpage>500</lpage>
          <pub-id pub-id-type="pmid">3700829</pub-id>
        </citation>
      </ref>
      <ref id="B13">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lynch</surname>
              <given-names>HT</given-names>
            </name>
            <name>
              <surname>Frichot</surname>
              <given-names>BC</given-names>
            </name>
            <name>
              <surname>Fisher</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>JL</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Lynch</surname>
              <given-names>JF</given-names>
            </name>
          </person-group>
          <article-title>Spontaneous regression of metastatic malignant melanoma in 2 sibs with xeroderma pigmentosum</article-title>
          <source>J Med Genet</source>
          <year>1978</year>
          <volume>15</volume>
          <fpage>357</fpage>
          <lpage>362</lpage>
          <pub-id pub-id-type="pmid">739525</pub-id>
        </citation>
      </ref>
      <ref id="B14">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bulkley</surname>
              <given-names>GB</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Banks</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Char</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Ketcham</surname>
              <given-names>AS</given-names>
            </name>
          </person-group>
          <article-title>Long-term spontaneous regression of malignant melanoma with visceral metastases. report of a case with immunologic profile</article-title>
          <source>Cancer</source>
          <year>1975</year>
          <volume>36</volume>
          <fpage>485</fpage>
          <lpage>494</lpage>
          <pub-id pub-id-type="pmid">1157014</pub-id>
          <pub-id pub-id-type="doi">10.1002/1097-0142(197508)36:2&lt;485::AID-CNCR2820360227&gt;3.0.CO;2-M</pub-id>
        </citation>
      </ref>
      <ref id="B15">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Atallah</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Flaherty</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Treatment of metastatic malignant melanoma</article-title>
          <source>Curr Treat Options Oncol</source>
          <year>2005</year>
          <volume>6</volume>
          <fpage>185</fpage>
          <lpage>193</lpage>
          <pub-id pub-id-type="pmid">15869730</pub-id>
          <pub-id pub-id-type="doi">10.1007/s11864-005-0002-5</pub-id>
        </citation>
      </ref>
      <ref id="B16">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lejeune</surname>
              <given-names>FJ</given-names>
            </name>
            <name>
              <surname>Rimoldi</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Speiser</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>New approaches in metastatic melanoma:biological and molecular targeted therapies</article-title>
          <source>Expert Rev Anticancer Ther</source>
          <year>2007</year>
          <volume>7</volume>
          <fpage>701</fpage>
          <lpage>713</lpage>
          <pub-id pub-id-type="pmid">17492933</pub-id>
          <pub-id pub-id-type="doi">10.1586/14737140.7.5.701</pub-id>
        </citation>
      </ref>
      <ref id="B17">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Parmiani</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Castelli</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Santinami</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Rivoltini</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Melanoma immunology: past, present and future</article-title>
          <source>Curr Opin Oncol</source>
          <year>2007</year>
          <volume>19</volume>
          <fpage>121</fpage>
          <lpage>127</lpage>
          <pub-id pub-id-type="pmid">17272984</pub-id>
          <pub-id pub-id-type="doi">10.1097/CCO.0b013e32801497d7</pub-id>
        </citation>
      </ref>
      <ref id="B18">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Speiser</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Lienard</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Rufer</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Rubio-Godoy</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Rimoldi</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Lejeune</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Frieg</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Cerottini</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Romero</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909</article-title>
          <source>J Clin Invest</source>
          <year>2005</year>
          <volume>115</volume>
          <fpage>739</fpage>
          <lpage>746</lpage>
          <pub-id pub-id-type="pmid">15696196</pub-id>
        </citation>
      </ref>
      <ref id="B19">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <collab>No Authors listed</collab>
          </person-group>
          <article-title>CpG 7909: PF 3512676 PF-3512676</article-title>
          <source>Drugs in R&amp;D</source>
          <year>2006</year>
          <volume>7</volume>
          <fpage>312</fpage>
          <lpage>316</lpage>
          <pub-id pub-id-type="pmid">16922592</pub-id>
        </citation>
      </ref>
      <ref id="B20">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brown</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Roda</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Terrell</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Chaudhury</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Crespin</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Carson</surname>
              <given-names>WE</given-names>
            </name>
            <name>
              <surname>Lesinski</surname>
              <given-names>GB</given-names>
            </name>
          </person-group>
          <article-title>Interferon &#xE1; and CPG oligodeoxynucleotides elicit additive immunostimulatory and antitumor effects</article-title>
          <source>Surgery</source>
          <year>2006</year>
          <volume>140</volume>
          <fpage>297</fpage>
          <lpage>306</lpage>
          <pub-id pub-id-type="pmid">16904983</pub-id>
          <pub-id pub-id-type="doi">10.1016/j.surg.2006.05.005</pub-id>
        </citation>
      </ref>
      <ref id="B21">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Molenkamp</surname>
              <given-names>BG</given-names>
            </name>
            <name>
              <surname>van Leeuwen</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Meijer</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sluijter</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Wijnands</surname>
              <given-names>PG</given-names>
            </name>
            <name>
              <surname>Baars</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>van den Eertwegh</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Scheper</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>de Gruijl</surname>
              <given-names>TD</given-names>
            </name>
          </person-group>
          <article-title>Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients</article-title>
          <source>Clin Cancer Res</source>
          <year>2007</year>
          <volume>13</volume>
          <fpage>2961</fpage>
          <lpage>2969</lpage>
          <pub-id pub-id-type="pmid">17504997</pub-id>
          <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-0050</pub-id>
        </citation>
      </ref>
      <ref id="B22">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pashenkov</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Go&#xEB;ss</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Wagner</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>H&#xF6;rmann</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Jandl</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Moser</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Britten</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Smolle</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Koller</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mauch</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Tantcheva-Poor</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Grabbe</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Loquai</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Esser</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Franckson</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Schneeberger</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Haarmann</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Krieg</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Stingl</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Wagner</surname>
              <given-names>SN</given-names>
            </name>
          </person-group>
          <article-title>Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma</article-title>
          <source>J Clin Oncol</source>
          <year>2006</year>
          <volume>24</volume>
          <fpage>5716</fpage>
          <lpage>5724</lpage>
          <pub-id pub-id-type="pmid">17179105</pub-id>
          <pub-id pub-id-type="doi">10.1200/JCO.2006.07.9129</pub-id>
        </citation>
      </ref>
      <ref id="B23">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kruit</surname>
              <given-names>WH</given-names>
            </name>
            <name>
              <surname>van Ojik</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Portielje</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Verloes</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Delire</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Stoter</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Phase I/II study with CpG 7909 as adjuvant to vaccination with MAGE-3 protein in patients with MAGE-3 positive tumors</article-title>
          <source>Proc Am Soc Clin Oncol</source>
          <year>2002</year>
          <volume>21</volume>
          <ext-link ext-link-type="uri" xlink:href="http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&amp;vmview=abst_detail_view&amp;confID=16&amp;index=y&amp;abstractID=1854"/>
          <comment>[abstr 1854]</comment>
        </citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
